FILGRASTIM - NEUTROMAX

Blastoferon is a recombinant human interferon, produced by mammalian mass cell culture technology. Interferon beta 1a is indicated for the treatment of relapsing recurrent multiple sclerosis.
Blastoferon product is available as a pre-filled syringe solution ready for subcutaneous injection and comes in...

Hemax is a synthetic form of human erythropoietin, used to treat anemia. Biosidus recombinant human erythropoietin, our flagship product, is obtained by mass cell culture of genetically modified mammalian cells. Our epoetin is available in a convenient thermostable formulation as freeze dried powder for in...

Somatropin is a sinthetic version of human growth hormone (hGH) which stimulates growth and cell reproduction in humans, also exerting its action on the metabolism of lipids, proteins and carbohydrates. Recombinant hGH (also known as somatropin) is produced by bacterial fermentation.
Somatropin Biosidu...

Filgrastim is a recombinant methionyl human granulocyte colony stimulating factor (r-Met-Hu-GCSF), produced by bacterial fermentation. Filgrastim is used to treat neutropenia, a side effect of chemotherapy, which makes patients more susceptible to bacterial infections.
Biosidus Filgrastim product is av...

Ready to use PFS containing Interferon Beta 1a for intramuscular injection. Each PFS contains interferon Beta 1a 30 µg 

Freeze dried vials containing 1K IU, 2K IU, 3K IU, 4K IU, 10 K IU; 20K IU; 40K IU

Freeze dried powder for reconstitution containint Somatropin 4 IU or Somatropin 16 IU

Single use vial ampoule containing azacitidine 100 mg freeze dried powder for IV/SC infusion. Antineoplastic, DNA Methylation Inhibitor

Vial ampoule of freeze dried powder containing Bortezomib 3.5 mg for IV injection

Freeze dried product containing interferon alfa 2b 3 M IU, 5 M IU or 10 M IU

Ready to use PFS containing Interferon Beta 1a. Each PFS contains interferon Beta 1a 22 µg (6 MIU) or 44 µg (12 MIU)

INTESTINAL PROBIOTIC

Todavía en etapa inicial, un equipo local, junto al Hospital de Clínicas y la Facultad de Medicina de la UBA, comienza la fase de ensayo exploratorio de una tecnología inhalable para tratar el coronavirus, en cualquiera de sus variantes

Las empresas argentinas ProinVet Innovations y Biosidus trabajan conjuntamente en una terapia inhalatoria para enfrentar el COVID-19

Institutional video that shows our state of the art production facilities and processes performed at Biosidus in Buenos Aires, Argentina